Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)

Stenosis Clinical Trial

— AVeVA  

Official title:

Prospective, Multi-Center Clinical Study of the Bard® COVERA™ Arteriovenous (AV) Stent Graft in the Treatment of Stenosis at the Graft-Vein Anastomosis of AV Graft Circuits (AVeVA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02790606
• Other study ID #: BPV-15-001
• Status: Completed
• Phase: N/A
• Start date: July 2016
• Est. completion date: March 16, 2019

Study information

• Verified date: April 2020
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the Arteriovenous (AV) access circuit.

Description:

This study will compare the use of the COVERA™ Vascular Covered Stent (following percutaneous transluminal angioplasty (PTA)) to safety and effectiveness performance goals (PGs) for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of subjects dialyzing with an AV graft.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: March 16, 2019
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Clinical Inclusion Criteria:

• Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.

• Subject must be either a male or non-pregnant female = 21 years of age with an expected lifespan sufficient to allow for completion of all study procedures.

• Subject must be willing to comply with the protocol requirements, including clinical and telephone follow-up.

• Subject must have a synthetic AV access graft located in an arm that has been implanted for = 30 days and must have undergone at least one successful dialysis session prior to the index procedure.

Angiographic Inclusion Criteria

• Subject must have angiographic evidence of a stenosis = 50% (by visual estimation) located at the graft-vein anastomosis of the subject's synthetic AV access graft and present with clinical evidence of graft dysfunction at the synthetic AV graft-vein anastomosis.

• The target lesion must be = 9cm in length. Note: multiple stenoses may exist within the target lesion.

• The reference vessel diameter of the adjacent non-stenotic vessel must be between 5.0 and 9.0mm.

Clinical Exclusion Criteria:

• The subject is dialyzing with an AV fistula.

• The hemodialysis access is located in the lower extremity.

• The subject has an infected AV access graft or uncontrolled systemic infection.

• The subject has a known uncontrolled blood coagulation/bleeding disorder.

• The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.

• The subject has a known hypersensitivity to nickel-titanium (Nitinol) or tantalum.

• The subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.

• The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.

Angiographic Exclusion Criteria:

• Additional stenotic lesions (= 50%) in the venous outflow that are > 3cm from the edge of the target lesion and are not successfully treated (defined as < 30% residual stenosis) prior to treating the target lesion.

• An aneurysm or pseudoaneurysm is present within the target lesion.

• The location of the target lesion would require the COVERA™ Vascular Covered Stent be deployed across the elbow joint.

• The target lesion is located within a stent or stent graft.

• The location of the target lesion would require that the COVERA™ Vascular Covered Stent be placed in the central veins (subclavian, brachiocephalic, Superior Vena Cava (SVC)) or under the clavicle at the thoracic outlet.

• There is incomplete expansion of an appropriately-sized angioplasty balloon to its expected profile, in the operator's judgment, during primary angioplasty at the target lesion prior to implantation of the study device.

Related Conditions & MeSH terms

• Constriction, Pathologic
• Restenosis
• Stenosis

Intervention

Device:
• Covera(TM) Vascular Covered Stent
Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.

Locations

Country	Name	City	State
United States	Surgical Specialists of Charlotte	Charlotte	North Carolina
United States	Chicago Access Care	Chicago	Illinois
United States	Tarrant Vascular Clinic	Fort Worth	Texas
United States	Jacksonville Center for Clinical Research	Jacksonville	Florida
United States	Ocala Kidney Group	Ocala	Florida
United States	St. Joseph Hospital	Orange	California
United States	Arizona Kidney Disease and Hypertension Center	Phoenix	Arizona
United States	Providence Access Care	Providence	Rhode Island
United States	NC Heart and Vascular Research	Raleigh	North Carolina
United States	NC Nephrology	Raleigh	North Carolina
United States	Capital Nephrology Access Center	Sacramento	California
United States	Clinical Advancement Center, PLLC	San Antonio	Texas
United States	Southwest Vascular Center	Tempe	Arizona
United States	Arizona Kidney Disease and Hypertension Center Medical Research Services, LLC	Tucson	Arizona
United States	Renal and Transplant Associates of New England, P.C.	West Springfield	Massachusetts
United States	The Cardiovascular Care Group	Westfield	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
C. R. Bard

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events	Safety is defined as freedom from any adverse event(s) (AEs), localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death.	30 days post index procedure
Primary	Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency	Target Lesion Primary Patency (TLPP) is defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access.; Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV access graft due to inability to treat the original treatment area.; The primary effectiveness endpoint is evaluated against a performance goal (PG) of 40%.	6 months post index procedure
Secondary	Endpoint Without Hypothesis Testing: Number of Participants With Target Lesion Primary Patency (TLPP)	TLPP is defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access.; Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV access graft due to inability to treat the original treatment area.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.	1, 3, 6, 12, 18 and 24 months post index procedure
Secondary	Endpoint With Hypothesis Testing: Number of Participants With Access Circuit Primary Patency (ACPP)	ACPP is defined as the interval following the index intervention until the next access thrombosis or repeated intervention.; ACPP ends with a reintervention anywhere within the access circuit. Vessel rupture caused by PTA is not an ACPP failure unless achieving hemostasis also causes thrombosis.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.	1, 3, 6, 12, 18 and 24 months post index procedure
Secondary	Endpoint Without Hypothesis Testing: Number of Participants With Device and Procedure Related AEs Involving the AV Access Circuit	Number of Participants with device and procedure related Adverse Events involving the AV access circuit.; The access circuit is the area from the arterial inflow to the SVC-right atrial junction.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.	1, 3, 6, 12, 18 and 24 months post index procedure,
Secondary	Endpoint Without Hypothesis Testing: Total Number of Arteriovenous (AV) Access Circuit Reinterventions	Total Number of AV Access Circuit Reinterventions defined as the number of reinterventions to the AV access circuit until access abandonment or through study completion.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.	1, 3, 6, 12, 18 and 24 months post index procedure.
Secondary	Endpoint Without Hypothesis Testing: Total Number of Target Lesion Reinterventions	Total Number of Target Lesion Reinterventions defined as the number of reinterventions to maintain target lesion patency.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.	1, 3, 6, 12, 18 and 24 months post index procedure
Secondary	Endpoint Without Hypothesis Testing: Index of Patency Function (IPF)	IPF is defined as the time from the index study procedure to study completion or access abandonment divided by the number of visits for a reintervention performed on the AV access circuit in order to maintain vascular access for hemodialysis.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.; The IPF is representative of the number of days between interventions to maintain access circuit patency. The minimum and maximum ranges for the Index of Patency Function are as follows: 1 month (6.3 - 30.0); 3 months (6.3 - 90.0); 6 months (6.3 - 180.0); 12 months (6.3 - 365.0); 18 months (6.3 - 545.0); and 24 months (6.3 - 730.0). Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.	1, 3, 6, 12, 18 and 24 months post index procedure
Secondary	Endpoint Without Hypothesis Testing: Index of Patency Function - Target Lesion (IPF-T)	IPF-T (Index of Patency Function - Target Lesion) is defined as the time from the index study procedure to study completion or complete access abandonment divided by the number of visits for a reintervention performed at the target lesion in order to maintain vascular access for hemodialysis.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.; The IPF for target lesion patency is representative of the approximate (mean) number of days between interventions to maintain target lesion patency. The minimum and maximum ranges for the Index of Patency Function are as follows: 1 month (6.3 - 30.0); 3 months (6.3 - 90.0); 6 months (6.3 - 180.0); 12 months (6.3 - 365.0); 18 months (6.3 - 545.0); and 24 months (6.3 - 730.0). Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.	1, 3, 6, 12, 18 and 24 months post index procedure
Secondary	Endpoint Without Hypothesis Testing: Number of Participants With Post-intervention Secondary Patency	Secondary Patency is defined as the interval after the index intervention until the access is abandoned. Multiple repetitive treatments can be included in post-intervention secondary patency.; The 1, 3, 6, 12, 18 and 24 months final results are reported below.	1, 3, 6, 12, 18 and 24 months post index procedure
Secondary	Endpoint Without Hypothesis Testing: Number of Participants With Technical Success (for Stent Graft Placement)	Technical Success is defined as successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure.	At time of index procedure
Secondary	Endpoint Without Hypothesis Testing: Number of Participants With Procedure Success	Procedure Success is defined as anatomic success and resolution of the pre-procedural clinical indicator(s) (clinical success) of a hemodynamically significant stenosis.	At time of index procedure